Novo Nordisk A/S

Novo Nordisk is a Danish pharmaceutical company focused on the research, development, manufacture, and distribution of pharmaceutical products. Its business is organized into two main segments: Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes Care segment provides products for diabetes, obesity, cardiovascular conditions, and emerging therapy areas. The Rare Disease segment offers treatments for rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Notable products include smart insulin pens like NovoPen 6 and NovoPen Echo Plus, the Dose Check insulin dose guidance app, and Wegovy, an oral GLP-1 receptor agonist for weight management. The company also produces growth hormone pens and injection needles.

Novo Nordisk is listed on the New York Stock Exchange (NYSE) under the ticker symbol NVO. Its shares are traded in US Dollars (USD). The company is headquartered in Bagsvaerd, Denmark, and its primary listing is on the NYSE, making it accessible to US investors. The use of USD as the trading currency simplifies investment for those in the United States and aligns with the exchange's standard currency.

Novo Nordisk operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This means the company is primarily involved in the research, development, production, and distribution of pharmaceutical drugs. As a drug manufacturer, it focuses on creating medications for various therapeutic areas, including diabetes, obesity, rare blood disorders, and rare endocrine disorders. Its industry classification reflects its role as a broad-based pharmaceutical company with a diverse portfolio of prescription medicines and related healthcare products.

Novo Nordisk is headquartered in Bagsvaerd, Denmark, and was founded in 1923. The company operates globally, serving markets across Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong, Taiwan, Latin America, the Middle East, and Africa. This extensive geographic reach allows Novo Nordisk to distribute its pharmaceutical products worldwide, with a strong presence in both developed and emerging markets. Its operations are tailored to meet regional healthcare needs, particularly in diabetes and obesity care.

Novo Nordisk generates revenue through the research, development, manufacture, and sale of pharmaceutical products. Its primary revenue streams come from two segments: Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes Care segment sells products for diabetes, obesity, cardiovascular conditions, and emerging therapy areas, including insulin pens, GLP-1 receptor agonists like Wegovy, and dose guidance apps. The Rare Disease segment contributes through treatments for rare blood disorders, rare endocrine disorders, and hormone replacement therapy, as well as smart insulin pens and growth hormone pens. The company's diverse portfolio and global distribution network enable it to generate income from prescription drug sales across multiple therapeutic areas.